Erin Cross

Erin Cross is Vice President of Platform at KROMATID, where she leads scientific development of advanced cytogenetic technologies and their application to genomic integrity assessment. KROMATID is pioneering analytical cytogenetics for cell and gene therapies, bringing chromosome-scale insights into therapeutic development and manufacturing. Erin's work focuses on translating these technologies into robust analytical methods that support therapeutic product characterization and quality assessment. She works closely with therapeutic developers to understand the genomic consequences of cell engineering and expansion, with an emphasis on identifying structural chromosomal abnormalities that may impact product quality and safety. She is passionate about advancing analytical cytogenetics as a critical component of developing safer, more effective cell and gene therapies.